TABLE 1

In vitro responses of leukemia cell lines and ex vivo and in vivo responses of pediatric ALL xenografts to ABT-737

Designation	Model Type	Leukemia Subtype	Cytogenetics of Original Patient Biopsy	Ex Vivo/In Vitro (IC₅₀)	In Vivo (25 mg/kg)		In Vivo (60 mg/kg)
Designation	Model Type	Leukemia Subtype	Cytogenetics of Original Patient Biopsy	Ex Vivo/In Vitro (IC₅₀)	LGD	P vs. Control	LGD	P vs. Control
ALL-2	Xenograft	c-ALL	46, XX, NAD	9.8 nM	2.7	0.4045	15.1	0.0059
ALL-3	Xenograft	Pre-B	46, XX, del(11;q23)	3.4 nM	27.4	<0.0001	30.7	<0.0001
ALL-4	Xenograft	Ph⁺-ALL	9q34(abl x2),22q11 (bcr x2)(abl con bcr x1)/9q34(abl x2),22q11(bcr x2)	16 nM	0.2	0.8216	12.0	0.0006
ALL-7	Xenograft	Biphen	46, XY, t(17;19)(q21;q13)	1.3 nM	20.6	<0.0001	23.7	0.0001
ALL-10	Xenograft	c-ALL	47, XY, +mar(12)/46, XY (13)	1.0 nM	12.9	<0.0001	24.8	<0.0001
ALL-11	Xenograft	c-ALL	46, XX, del(12p13), del(13q12) (8)/46, XX	45 nM	6.7	0.0257	29.4	0.0006
ALL-17	Xenograft	c-ALL	N.D.	3.7 nM	13.9	0.0002	14.3	0.0734
ALL-18	Xenograft	c-ALL	N.D.	3.0 nM	N.D.	N.D.	N.D.	N.D.
ALL-19	Xenograft	c-ALL	46, XY, NAD	5.5 nM	0.2	0.9175	14.5	0.0001
HL-60	Cell Line	AML	N.D.	>10 μM	N.D.	N.D.	N.D.	N.D.
K562	Cell Line	CML	N.D.	>10 μM	N.D.	N.D.	N.D.	N.D.
Nalm6	Cell Line	Pre-B	N.D.	>10 μM	N.D.	N.D.	N.D.	N.D.
Jurkat	Cell Line	T-ALL	N.D.	5 μM	N.D.	N.D.	N.D.	N.D.
Molt4	Cell Line	T-ALL	N.D.	918 nM	N.D.	N.D.	N.D.	N.D.
REH	Cell Line	Pre-B	N.D.	677 nM	N.D.	N.D.	N.D.	N.D.
CEM	Cell Line	T-ALL	N.D.	303 nM	N.D.	N.D.	N.D.	N.D.
Hal-01	Cell Line	Pro-B	N.D.	192 nM	N.D.	N.D.	N.D.	N.D.

AML, acute myelogenous leukemia; Biphen-ALL, biphenotypic ALL; CML, chronic myelogenous leukemia; c-ALL, common (CD10⁺) pre-B ALL; NAD, no abnormality detected; N.D., not done; Ph⁺-ALL, Philadelphia chromosome-positive ALL; Pre-B, B-cell precursor ALL.